Sitagliptin: a potential drug for the treatment of COVID-19?
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical lite...
Saved in:
Main Authors: | Bardaweel Sanaa K., Hajjo Rima, Sabbah Dima A. |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2021-06-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2021-0013 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
by: Soumitra Ray, et al.
Published: (2024-04-01) -
A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats
by: Stavros K Kourkoulis, et al.
Published: (2020-01-01) -
Recent developments in the therapeutics of SARS-CoV-2 infection
by: Priyanka Nagu, et al.
Published: (2024-12-01) -
Oxidative Stress and Its Association with COVID-19: A Narrative Review
by: Hardi Rafat Baqi, et al.
Published: (2020-06-01) -
Autoantibodies in COVID-19: implications for disease severity and clinical outcomes
by: Yannick Galipeau, et al.
Published: (2025-01-01)